CXCR4 and acute myeloid leukemia: Its analog AMD3465 demonstrated remarkable activity in antagonizing CXCL12-induced CXCR4 signaling pathways, mobilizing AML cells into circulation and enhancing anti-leukemic effects of chemotherapy in vitro and in vivo19, 20.